Products & ReviewClinical Diagnostics

LIAISON® SARS-CoV-2 TrimericS IgG

The LIAISON® SARS-CoV-2 TrimericS IgG assay enables the reliable detection of Trimeric S spike protein IgG antibodies – the body’s natural defense response against SARS-CoV-2.

DiaSorin Ltd

The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our  Product Directory.

Ease of Use
After Sales Service
Value for Money
Write your own review

A quantitative assay for immune status monitoring with an accurate correlation of neutralizing IgG antibodies

The LIAISON® SARS-CoV-2 TrimericS IgG assay is the second generation of DiaSorin serological tests with an important diagnostics improvement. The selection of a new recombinant Trimeric Spike glycoprotein as a capture antigen, offers a new product with high standard quality that provides the following benefits:

  • A quantitative assay for the detection of IgG antibodies anti-Trimeric Spike glycoprotein of SARS-CoV-2
  • Trimeric Spike Glycoprotein is the stabilized native form of the SARS-CoV-2 Spike protein and a stabilized trimer may elicit an accurate detection of IgG Neutralizing antibodies
  • Clinical Sensitivity: 98.7% - Clinical Specificity: 99.5%
  • Correlation with Microneutralization test: PPA: 100%, NPA: 96.9%
  • A fully automated solution with up to 171 results/hour on LIAISON® XL
  • Complete traceability combined with a simplified sample workflow

Product Overview

Links